Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
KRAS G12D, the most frequent KRAS oncogenic mutation, is a promising target for cancer therapy. Herein, we report the design, synthesis, and biological evaluation of a series of KRAS G12D PROTACs by connecting the analogues of MRTX1133 and the VHL ligand. Structural modifications of the linker moiety and KRAS inhibitor part suggested a critical role of membrane permeability in the degradation activity of the KRAS G12D PROTACs. Mechanism studies with the representative compound 8o demonstrated that the potent, rapid, and selective degradation of KRAS G12D induced by 8o was via a VHL- and proteasome-dependent manner. This compound selectively and potently suppressed the growth of multiple KRAS G12D mutant cancer cells, displayed favorable pharmacokinetic and pharmacodynamic properties in mice, and showed significant antitumor efficacy in the AsPC-1 xenograft mouse model. Further optimization of 8o appears to be promising for the development of a new chemotherapy for KRAS G12D -driven cancers as the complementary therapeutic strategy to KRAS inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PROTAC (proteolysis-targeting chimera) technologies are designed to induce selective degradation of KRAS proteins through recruitment of E3 ubiquitin ligases and subsequent proteasomal destruction [61,62,63,64].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [63]
Citations
Cites
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationRegulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Guanine nucleotide exchange factors for Rho GTPases: turning on the switch
Schmidt, A., & Hall, A. (2002) · Genes & Development · doi:10.1101/gad.1003302 · Cited by 1,241
Cited by
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 115
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 61
Liu, Y., Han, J., Hsu, W., LaBella, K. A., Deng, P., Shang, X., de Lara, P. T., Cai, L., Jiang, S., & DePinho, R. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0489 · Cited by 47
Feng, J., Xiao, X., Xia, X., Min, J., Tang, W., Shi, X., Xu, K., Zhou, G., Li, K., Shen, P., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.006 · Cited by 46
Self-citationLondon, N. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00570 · Cited by 39
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Li, Y., Wu, Y., Gao, S., Sun, T., & Jiang, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.076 · Cited by 32
Self-citationDiscovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
Ji, X. L., Li, H., Wu, G., Zhang, Q., He, X., Wu, Y., Zong, B., Xu, X., Liang, C., Wang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00428 · Cited by 32
Kudo, G., Hirao, T., Harada, R., Shigeta, Y., Hirokawa, T., & Yoshino, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00102 · Cited by 18
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 21
Development of PROTACS degrading KRAS and SOS1
Hamilton, G., Eggerstorfer, M.-T., & Stickler, S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.051653 · Cited by 18
Karpińska, K., Mehlich, D., Sabbasani, V. R., Łomiak, M., Torres‐Ayuso, P., Wróbel, K., Truong, V. N.-P., Serwa, R. A., Swenson, R. E., Brognard, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00577 · Cited by 12
ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer
Liu, Z., Zheng, H., Tian, Y., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01034 · Cited by 14
Self-citationKRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants
Jeon, E., Kim, C., Ko, M., Kim, T. K., Bae, J., Oh, J. W., Kim, K. P., Kim, H. S., & Sim, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117928 · Cited by 10
Kumar, V., Danodia, A. K., Jadhavar, P. S., Mohanty, S. K., & Samanta, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118555 · Cited by 8
Xie, L., Xu, C., Si, H., Fu, X., Yang, X., Jin, J., Yu, X., Shao, Z., Wang, Y., Chu, T., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1346 · Cited by 9
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 8
Alshahrani, M., Parikh, V., Foley, B., Hu, G., & Verkhivker, G. M. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00966a · Cited by 7
Inhibition of GTPase KRAS G12D : a review of patent literature
Li, Y., Yang, L., Li, X., & Zhang, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2369630 · Cited by 9
Self-citationRecent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 7
Self-citationAn overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Han, Z., Wu, Q., Rao, H., Xu, T., & Zhou, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130283 · Cited by 5
Self-citationStructure–activity relationships of KRAS-G12D inhibitors for pancreatic cancer
Suyal, C., Mangala, S. S., Kishore, A., & Kini, S. G. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104396 · Cited by 7
Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance
Chidambaram, K., Rekha, A., Goyal, A., & Rana, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155954 · Cited by 5
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450 · Cited by 4
Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers
Jiang, L., Chen, Y., Zhao, J., Zhou, L., Zhou, Q., Jiang, H., Lou, D., Huang, W., & Zhang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109161 · Cited by 7
Yang, H., Gan, L., & Zhang, H. (2025) · Pharmaceuticals · doi:10.3390/ph18050696 · Cited by 5
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 4
Discovery of KRAS-G12D degraders via exploration of various E3 ligases
Yim, H., Song, X., Zhong, Y., Hu, J., Xiong, Y., & Jin, J. J. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118635 · Cited by 3
Prospects and advances of PROTAC in the treatment of hematologic malignancies
Wang, X., Zhang, M., & Mei, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00759-3 · Cited by 3
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
Martín, A., García-Pérez, I. M., José, S. S., Rojo, P., Riego‐Mejías, C., Teodósio, C., Barbosa, B. M. G., Sánchez, C., Folch-I-Casanovas, I., Odena, M. A., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5172 · Cited by 4
Gu, Y., Li, C., Zhao, Y., Xu, T., Zhu, Y., Wang, D., Wang, X., Chen, J., Li, J., & Guan, X. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102948 · Cited by 3
Self-citationZhou, J., Fang, Z., Zhang, W., Rao, G.-W., & Zheng, Q. (2025) · Mini-Reviews in Organic Chemistry · doi:10.2174/0118756298391640250731025705 · Cited by 1
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450.2
PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugsPreprint
Simón-Carrasco, L., Raya, S., Pietrini, E., Luque-Perez, M., Oliva, M. D. R., Rosado, I., & Lopez-Contreras, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.698947
Research Progress of Proteolysis‐Targeting Chimera Technology and Its Linkers in Cancer Therapy
Yang, J., & Zhang, X. (2026) · ChemMedChem · doi:10.1002/cmdc.70291
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation
Jiang, L., Yang, W., Liu, Y., Li, G., Luo, X., Zhou, Y., Qin, J., Pan, Y., & Huang, W. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107633
Wang, C., Ghosh, P., Jin, S., Bai, L., Aguilar, A., McEachern, D., Wang, M., Li, Q., Wen, B., Sun, D., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01153
Jeon, E., Song, J., & Sim, T. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2719780
Fouad, M. A. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118508
Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues
Hao, S., Niu, T., Wu, X., Mu, C., Wang, M., Liu, H., & 路海滨 (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110633
Zheng, H., Liu, Z., Nie, S., Sun, J., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2026) · Marine Life Science & Technology · doi:10.1007/s42995-026-00424-y
Self-citationBindingDB (2026) · UC San Diego · doi:10.7270/q2m90fn6
Metadata
- Authors
- Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., Wang, D., He, W., Zheng, M., Zhang, S., & Xu, T.
- Affiliations
- Chinese Academy of Sciences (CN)
- The University of Texas at El Paso (US)
- Nanjing University of Chinese Medicine (CN)
- Nanchang University (CN)
- Corresponding author
- Zheng, Mingyue
- Zhang, Sulin
- Xu, Tianfeng
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-01-10
- Volume
- 67
- Issue
- 2
- Pages
- 1147-1167
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4390705036
- Cited by
- 45
- References
- 48
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 12
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2023296)
- National Natural Science Foundation of China (22107110, T2225002)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- PROTAC degraders, KRAS G12D, oncogenic KRAS, MRTX1133, linker optimization, membrane permeability, proteasomal degradation, KRAS inhibitors, antitumor efficacy, KRAS-driven cancers
- MeSH terms
- Animals, Disease Models, Animal, Heterocyclic Compounds, 2-Ring, Humans, Mutation, Naphthalenes, Proto-Oncogene Proteins p21(ras), Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.